ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,158.80
1.06%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.125
-0.03%
Bitcoin
64,399.75
-0.13%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) Quote

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
20.57
-0.22
(-1.06%)
Closed April 25 4:00PM
Delayed by 15 minutes
20.57
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
20.57
Bid
19.56
Ask
20.96
Volume
-
0.00 Day's Range 0.00
11.215 52 Week Range 25.34
Market Cap
1.748B
Previous Close
20.57
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,091,847
Shares Outstanding
84,965,486
Dividend Yield
-
PE Ratio
-8.35
Earnings Per Share (EPS)
-2.46
Revenue
-
Net Profit
-209.36M

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.syndax.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was $20.57. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of $ 11.215 to $ 25.34.

Syndax Pharmaceuticals currently has 84,965,486 shares outstanding. The market capitalization of Syndax Pharmaceuticals is $1.75 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -8.35.

Syndax Pharmaceuticals (SNDX) Options Flow Summary

SNDX Options Flow

Overall Flow

Bullish

Net Premium

27k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

SNDX Latest News

More News

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass., April 10, 2024 WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...

April 10 2024
PR Newswire (US)

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire WALTHAM, Mass., April 8, 2024...

April 08 2024
PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., April 5, 2024 WALTHAM, Mass., April 5, 2024 /PRNewswire/ -- Syndax...

April 05 2024
PR Newswire (US)

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia PR Newswire WALTHAM, Mass., March 28, 2024 –...

March 28 2024
PR Newswire (US)

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire WALTHAM, Mass., March 26, 2024 – PDUFA action date set for...

March 26 2024
PR Newswire (US)

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer PR Newswire WALTHAM, Mass., March 18, 2024 – Steven Closter brings more than 30 years of commercial experience in the...

March 18 2024
PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., March 1, 2024 WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Syndax...

March 01 2024
PR Newswire (US)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

February 27 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.160.7839294463520.4121.5420.1368652020.83390396CS
4-3.1-13.096746937123.6724.37520.1388924321.95359677CS
12-0.26-1.2481997119520.8325.3420.085109184722.6665305CS
268.5871.559633027511.9925.3411.96135720819.85690494CS
52-0.51-2.4193548387121.0825.3411.215129215318.50859688CS
1565.2534.268929503915.3229.8611.21586136519.36429553CS
26013.76202.0558002946.8129.865.3569323718.84609192CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3559
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.58
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.68
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5801
(0.00%)
0
AACGATA Creativity Global
$ 0.8801
(0.00%)
0

SNDX Discussion

View Posts
dinogreeves dinogreeves 7 months ago
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
👍️0
dinogreeves dinogreeves 7 months ago
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
👍️0
dealerschool2006 dealerschool2006 3 years ago
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
👍️0
dealerschool2006 dealerschool2006 3 years ago
SNDX recovering from panic sale!!!
👍️0
dealerschool2006 dealerschool2006 3 years ago
Panic sale for SNDX on positive results...May options wide swings...
👍️0
DaytraderJohn DaytraderJohn 4 years ago
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
👍️0
ClayTrader ClayTrader 4 years ago
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX next week is going to be fun
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX holding this baby!
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX keep climbing baby! Going be going up all next week
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX looking awesome from my call at $8.00
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX got us a runner folks!!!
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX Chomp Chomp Chomp!
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX Weeeeeeeeeee
👍️0
BoilerRoom BoilerRoom 4 years ago
Going to run folks.
👍️0
BoilerRoom BoilerRoom 4 years ago
$SNDX in at $8.00
👍️0
TheFinalCD TheFinalCD 4 years ago
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
👍️0
whytestocks whytestocks 5 years ago
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
👍️0
DewDiligence DewDiligence 5 years ago
SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
👍️0
Spartak Spartak 6 years ago
Well, the company is done. What a disaster.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
👍️0
DewDiligence DewDiligence 6 years ago
#msg-143766395
👍️0
DewDiligence DewDiligence 6 years ago
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
👍️0
DewDiligence DewDiligence 6 years ago
#msg-143642544
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
👍️0
Spartak Spartak 6 years ago
When does pounding stop? Someone hummers it pretty badly.
👍️0
fsantes fsantes 6 years ago
Ill keep a look out for some then!... I’ve been looking as well. Thank you!
👍️0
DewDiligence DewDiligence 6 years ago
No. I generally post anything that's material.
👍️0
fsantes fsantes 6 years ago
Have you heard any new news on SNDX?
👍️0
fsantes fsantes 6 years ago
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
👍️0
DewDiligence DewDiligence 6 years ago
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
👍️0
fsantes fsantes 6 years ago
Do you know what’s the news that came out about? When I look it’s blank..
👍️0
DewDiligence DewDiligence 6 years ago
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
👍️0
tika1 tika1 6 years ago
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
👍️0
DewDiligence DewDiligence 6 years ago
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
👍️0
DewDiligence DewDiligence 6 years ago
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
👍️0
DewDiligence DewDiligence 6 years ago
Yes—please see my reply in #msg-140012720.
👍️0
tika1 tika1 6 years ago
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
👍️0
DewDiligence DewDiligence 6 years ago
The annual-report proxy has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/bp05609x1_proxy.htm
👍️0
DewDiligence DewDiligence 6 years ago
The 2017 10-K has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/sndx-10k_20171231.htm
👍️0

Your Recent History

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved